EXPAND AND CONSOLIDATE GLOBAL FOOTPRINT

to provide access to quality medicines at an affordable price

Konw More

About IMSDA

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

In The News

India Pharma 2026: CDSCO Fast-Track Trials, Biosimilar Guidelines, and Innovation Agenda - The Indian pharmaceutical sector is undergoing a significant transformation in 2026, driven by landmark regulatory reforms from the Central Drugs Standard Control Organization (CDSCO), new clinical trial fast-track rules, updated biosimilar guidelines, and a government-wide push for innovation-led growth. Health Minister J P Nadda recently affirmed that India is “well-positioned in the pharma industry” amid […]
USFDA Seeks Indian Pharma Help for Critical Cancer Drug Shortage - The United States Food and Drug Administration (USFDA) has approached Indian pharmaceutical manufacturers to address a critical shortage of ifosfamide, a chemotherapy drug essential for treating testicular cancer, lung cancer, and certain sarcomas. This development underscores India’s growing role as the global pharmacy in times of medicine supply crises, with multiple Indian drugmakers preparing to […]
Indian Pharma’s Strategic Pivot from Generics to Specialty Drugs and Biosimilars - Indian pharmaceutical companies, long celebrated as the “pharmacy of the world” for their affordable generic medicines, are now charting a strategic course toward specialty drugs, biosimilars, and innovative therapies. This shift, driven by pricing pressures in the US generics market and a wave of patent expirations, marks one of the most significant transformations in the […]
Indian Pharma’s $19.1B US Push Amid Generics Tariff Exemption - 🇺🇸 US Imposes 100% Tariff on Patented Drug Imports from India In a major trade policy shift, the United States imposed a 100% tariff on patented pharmaceutical products imported from India, effective April 2, 2026. The move, announced under Section 232 of the Trade Expansion Act of 1962, cites national security risks from foreign dependency […]
Read More

Our Videos

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

Stay Connected

If you have any question,please connect us.

Connect Us

Join Us

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Join Us